TW200504078A - Therapeutically active compounds and their use - Google Patents

Therapeutically active compounds and their use

Info

Publication number
TW200504078A
TW200504078A TW093116412A TW93116412A TW200504078A TW 200504078 A TW200504078 A TW 200504078A TW 093116412 A TW093116412 A TW 093116412A TW 93116412 A TW93116412 A TW 93116412A TW 200504078 A TW200504078 A TW 200504078A
Authority
TW
Taiwan
Prior art keywords
active compounds
type
therapeutically active
hsd
disorder
Prior art date
Application number
TW093116412A
Other languages
English (en)
Chinese (zh)
Inventor
Kristiina Wahala
Annamaria Lilienkampf
Sari Alho
Kaisa Huhtinen
Nina Johansson
Pasi Koskimies
Kimmo Vihko
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of TW200504078A publication Critical patent/TW200504078A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
TW093116412A 2003-06-10 2004-06-08 Therapeutically active compounds and their use TW200504078A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47701703P 2003-06-10 2003-06-10

Publications (1)

Publication Number Publication Date
TW200504078A true TW200504078A (en) 2005-02-01

Family

ID=33551663

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093116412A TW200504078A (en) 2003-06-10 2004-06-08 Therapeutically active compounds and their use

Country Status (17)

Country Link
US (3) US7754709B2 (enExample)
EP (1) EP1635840B1 (enExample)
JP (1) JP4612628B2 (enExample)
CN (1) CN100502876C (enExample)
AR (1) AR044649A1 (enExample)
AT (1) ATE401893T1 (enExample)
AU (1) AU2004246791B2 (enExample)
BR (1) BRPI0411319A (enExample)
CA (1) CA2527591A1 (enExample)
DE (1) DE602004015287D1 (enExample)
DK (1) DK1635840T3 (enExample)
ES (1) ES2311156T3 (enExample)
PL (1) PL1635840T3 (enExample)
PT (1) PT1635840E (enExample)
SA (1) SA04250158B1 (enExample)
TW (1) TW200504078A (enExample)
WO (1) WO2004110459A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
WO2006044826A2 (en) * 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
BRPI0419229A (pt) * 2004-12-13 2007-12-18 Solvay Pharm Gmbh derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
CA2643670A1 (en) * 2006-02-27 2007-08-30 Sterix Limited Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer
EP1990335A4 (en) 2006-03-02 2009-11-11 Astellas Pharma Inc 17-BETA-HSD-type-5 INHIBITOR
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
DE102007040243A1 (de) 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
AU2009243812B2 (en) * 2008-05-05 2014-06-05 Merck Patent Gmbh NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP2609089A1 (en) 2010-08-27 2013-07-03 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012119605A1 (en) * 2011-03-10 2012-09-13 Akar Yahya Ahmed Abdellhafeez Salem New disperse dye with potent anticancer activity
JP6456373B2 (ja) 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
AR096728A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados de estratrieno-tiazol terapéuticamente activos
AR096729A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados terapéuticamente activos de estratien-tiazol
EP3089969A2 (en) 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
JP2017527606A (ja) * 2014-09-18 2017-09-21 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 三環系誘導体
JP6523461B2 (ja) 2014-12-23 2019-06-05 フォレンド ファーマ リミテッド １７β−ＨＳＤ１−阻害剤のプロドラッグ
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
RU2019135845A (ru) * 2017-04-11 2021-05-11 Ридженерон Фармасьютикалз, Инк. Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b)
DK3634975T3 (da) 2017-06-08 2024-05-27 Organon R&D Finland Ltd 17-oximer af 15.beta.-[3-propanamido]-substituerede estra-1,3,5(10)-trien-17-oner til anvendelse i inhibition af 17.beta.-hydroxysteroid-dehydrogenaser
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
US12359201B2 (en) 2018-03-21 2025-07-15 Regeneron Pharmaceuticals, Inc. 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN109180702B (zh) * 2018-10-29 2021-11-30 四川大学 一种噻吩并嘧啶酮化合物及其用途
CA3122049C (en) 2018-12-05 2023-10-17 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
BR112022003729A2 (pt) * 2019-10-15 2022-05-31 Boehringer Ingelheim Int Tienopirimidonas como inibidores de trpa1
WO2021074198A1 (en) 2019-10-15 2021-04-22 Boehringer Ingelheim International Gmbh Novel tetrazoles
CA3210965A1 (en) 2021-04-14 2022-10-20 Boehringer Ingelheim International Gmbh 3h,4h-thieno[2,3-d]pyrimidin-4-one derivatives as trpa1 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4742271B1 (enExample) * 1968-06-20 1972-10-25
DE2411273A1 (de) * 1974-03-06 1975-09-18 Schering Ag Neue thieno eckige klammer auf 2,3-d eckige klammer zu pyrimidinone und verfahren zu ihrer herstellung
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
JP3783810B2 (ja) 1997-01-14 2006-06-07 第一製薬株式会社 新規ベンゾフラノン誘導体及びその製造方法
JPH10273467A (ja) 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
AU9001698A (en) 1997-09-11 1999-03-29 Snow Brand Milk Products Co., Ltd. Remedies for hormone-dependent diseases
TR200002784T2 (tr) * 1998-03-11 2000-12-21 Endorecherche, Inc Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
GB9816729D0 (en) 1998-08-01 1998-09-30 Hoechst Schering Agrevo Gmbh Substituted cyclohexylaminopyrimidines
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
AU2001296961A1 (en) 2000-09-29 2002-04-08 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
ES2276950T3 (es) * 2001-09-06 2007-07-01 Schering Corporation Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
US6750248B2 (en) * 2001-11-09 2004-06-15 National University Of Singapore Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof
FI20030393L (fi) 2003-03-14 2004-09-15 Molekyyliendokrinologian Tutki Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
GB0324792D0 (en) * 2003-10-23 2003-11-26 Sterix Ltd Compound
BRPI0510394A (pt) * 2004-05-24 2007-11-13 Amgen Inc inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1

Also Published As

Publication number Publication date
US20050032778A1 (en) 2005-02-10
US20080103131A1 (en) 2008-05-01
AU2004246791A1 (en) 2004-12-23
HK1087331A1 (zh) 2006-10-13
WO2004110459A1 (en) 2004-12-23
DE602004015287D1 (en) 2008-09-04
CN100502876C (zh) 2009-06-24
AU2004246791B2 (en) 2010-02-18
EP1635840B1 (en) 2008-07-23
US20100249106A1 (en) 2010-09-30
AR044649A1 (es) 2005-09-21
ES2311156T3 (es) 2009-02-01
CA2527591A1 (en) 2004-12-23
SA04250158B1 (ar) 2007-10-29
US7754709B2 (en) 2010-07-13
JP2006527227A (ja) 2006-11-30
PL1635840T3 (pl) 2009-01-30
ATE401893T1 (de) 2008-08-15
CN1784234A (zh) 2006-06-07
EP1635840A1 (en) 2006-03-22
PT1635840E (pt) 2008-09-17
DK1635840T3 (da) 2008-09-01
BRPI0411319A (pt) 2006-07-18
JP4612628B2 (ja) 2011-01-12

Similar Documents

Publication Publication Date Title
TW200504078A (en) Therapeutically active compounds and their use
TW200509937A (en) Novel compounds and their use in therapy
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
GB0223038D0 (en) Therapeutic compounds
GB0223040D0 (en) Therapeutic compounds
WO2004006858A3 (en) Compounds, compositions, and methods employing same
PL370111A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
MXPA05006359A (es) Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
AU7031500A (en) Therapeutic quinazoline compounds
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
AU2386201A (en) Substituted sapogenins and their use
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
AUPS057102A0 (en) Compositions and methods for treatment of skin disorders
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
SE9603725D0 (sv) New teatment
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
ZA200209714B (en) Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV.
WO2004012732A3 (en) Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis